文献速递神经肿瘤神经重症

血脑屏障异质性递送限制EGFR靶向抗体药物偶联物在胶质母细胞瘤中的疗效

Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
PubMed 文献 · Neuro Oncol · 2021-01-01

该研究利用PDX模型比较Depatux-M全身与颅内递送的疗效,发现全身给药在异位肿瘤中高度有效,但颅内肿瘤疗效差与药物分布有限且异质相关;人工破坏血脑屏障或直接颅内注射可显著增强疗效。

要点

  • Depatux-M全身给药在多数EGFR扩增异位PDX中有效,但颅内PDX响应率低。
  • 颅内疗效差与药物在肿瘤组织内分布有限且异质相关。
  • 破坏血脑屏障或颅内直接注射可显著增强Depatux-M疗效。

核心结论

  • 尽管Depatux-M具有强内在敏感性,但药物递送入脑肿瘤有限可能是近期临床试验失败的关键原因。

研究设计与样本

  • 采用PDX模型研究Depatux-M全身与颅内递送的疗效。
  • 使用免疫荧光和MALDI-MSI检测脑内药物水平。
  • 使用定量流式细胞术、Western blots、RNAseq、FISH和磷酸蛋白质组学研究EGFR水平及补偿通路。

主要发现

  • 全身递送Depatux-M在10个EGFR扩增异位PDX中的9个高度有效,8个PDX生存期超过一年。
  • 两个PDX(GBM12和GBM46)获得性耐药由EGFR表达抑制或出现缺乏Depatux-M抗体表位的新型EGFR短变体驱动。
  • 7个内在敏感PDX中仅2个对Depatux-M颅内肿瘤治疗有响应。
  • 颅内PDX疗效差与Depatux-M在肿瘤组织中分布有限且异质相关。
  • 人工破坏血脑屏障或直接颅内注射Depatux-M至原位肿瘤可显著增强疗效。

临床怎么用

  • 对于EGFR扩增胶质母细胞瘤,需关注血脑屏障对Depatux-M递送的限制。
  • 破坏血脑屏障或局部递送可能增强Depatux-M疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antibody drug conjugates (ADCs) targeting the epidermal growth factor receptor (EGFR), such as depatuxizumab mafodotin (Depatux-M), is a promising therapeutic strategy for glioblastoma (GBM) but recent clinical trials did not demonstrate a survival benefit. Understanding the mechanisms of failure for this promising strategy is critically important. METHODS: PDX models were employed to study efficacy of systemic vs intracranial delivery of Depatux-M. Immunofluorescence and MALDI-MSI were performed to detect drug levels in the brain. EGFR levels and compensatory pathways were studied using quantitative flow cytometry, Western blots, RNAseq, FISH, and phosphoproteomics. RESULTS: Systemic delivery of Depatux-M was highly effective in nine of 10 EGFR-amplified heterotopic PDXs with survival extending beyond one year in eight PDXs. Acquired resistance in two PDXs (GBM12 and GBM46) was driven by suppression of EGFR expression or emergence of a novel short-variant of EGFR lacking the epitope for the Depatux-M antibody. In contrast to the profound benefit observed in heterotopic tumors, only two of seven intrinsically sensitive PDXs were responsive to Depatux-M as intracranial tumors. Poor efficacy in orthotopic PDXs was associated with limited and heterogeneous distribution of Depatux-M into tumor tissues, and artificial disruption of the BBB or bypass of the BBB by direct intracranial injection of Depatux-M into orthotopic tumors markedly enhanced the efficacy of drug treatment. CONCLUSIONS: Despite profound intrinsic sensitivity to Depatux-M, limited drug delivery into brain tumor may have been a key contributor to lack of efficacy in recently failed clinical trials.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Marin BM, Porath KA, Jain S, et al. Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. Neuro Oncol. 2021. PMID: 34050676. doi:10.1093/neuonc/noab133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。